According to AMR’s prediction, Hormone-refractory prostate cancer, also known as castration-resistant prostate cancer (CRPC), is a type of prostate cancer that no longer responds to hormonal therapies used to reduce levels of androgens, such as testosterone. Prostate cancer cells require androgens to grow and divide, and hormone therapy is often used as a first-line treatment to block the production or action of these hormones. However, over time, some prostate cancer cells may develop resistance to hormone therapy, leading to the progression of the disease.
♦ 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞:
https://www.alliedmarketresearch.com/request-toc-and-sample/1446
Hormone-refractory prostate cancer can cause a range of symptoms, including bone pain, fatigue, weight loss, and urinary problems. Treatment options for hormone-refractory prostate cancer include chemotherapy, immunotherapy, and newer targeted therapies that are designed to attack specific molecular targets involved in cancer growth and survival.
It’s important for patients with hormone-refractory prostate cancer to work closely with their healthcare providers to determine the best treatment options based on their individual needs and preferences. Clinical trials may also be available for patients who have exhausted standard treatment options.
The market is expected to register substantial growth attributed to the strategies adopted by leading market players. One of the key strategies adopted is collaboration agreement. For instance, in 2009, Astellas Pharma Inc. entered into an agreement with Medivation, Inc. to co-develop and co-commercialize MDV3100 (now Xtandi) for the treatment of HRPCA.
Key Market Players –
Major key players that operate in the industry are Astellas Inc., Sanofi S.A, Dendreon Corporation, Bayer AG, Johnson & Johnson.
♦ 𝐅𝐨𝐫 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲 𝐨𝐟 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.alliedmarketresearch.com/purchase-enquiry/1446
By Region –
North America (U.S., Canada, Mexico)
Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
LAMEA (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Asia-Pacific (Japan, China, Australia, India, South Korea, Rest of Asia-Pacific)
Frequently Asked Questions?
Q1. What is the total market value of global Hormone Refractory Prostate Cancer (HRPCA) Market?
Q2. Which market holds the maximum market share of the global Hormone Refractory Prostate Cancer (HRPCA) Market?
Q3. What will be global Hormone Refractory Prostate Cancer (HRPCA) Market growth in 2030?
Q4. What are the key trends in the global Hormone Refractory Prostate Cancer (HRPCA) Market?
Q5. What are the key growth strategies of global Hormone Refractory Prostate Cancer (HRPCA) Market players?
Q6. How the company profile has been selected?
♦ Procure Complete Report (220 Pages PDF with Insights, Charts, Tables, and Figures) @
https://www.alliedmarketresearch.com/checkout-final/db5eee5aad8a786a33892937afa2c8f5
About Us –
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various research data tables and confirms utmost accuracy in our market forecasting. Each and every us companies and this helps us in digging out market data that helps us generate accurate y data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com